Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Anaphase-promoting complex subunit 4 (ANAPC4) is a core component of the anaphase-promoting complex/cyclosome (APC/C), a multi-subunit E3 ubiquitin ligase essential for cell cycle regulation. The APC/C complex orchestrates the transition from metaphase to anaphase by targeting key regulatory proteins such as mitotic cyclins and anaphase inhibitors for ubiquitination, leading to their degradation by the 26S proteasome[1][2][3][4]. ANAPC4 itself does not have direct catalytic activity but is crucial for the assembly and function of the APC/C and thereby for proper cell cycle progression. Mutations or altered expression of ANAPC4 are associated with cell cycle dysregulation, tumor progression, and therapeutic resistance, especially in various cancers. The gene is conserved across eukaryotes, and disruption of its function affects mitosis and can lead to developmental disorders such as Adams-Oliver syndrome[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Anaphase-promoting complex subunit 4 (ANAPC4).